Screening of small molecule compounds that inhibits interaction between PD-1 and PD-L1

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K21235
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Drug development chemistry; Biological pharmacy
• Research Institution: The University of Tokushima
• Principal Investigator: MATSUSHITA Yosuke 徳島大学, 先端酵素学研究所(プロテオ), 助教 (70634450)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 化合物スクリーニング / 免疫チェックポイント阻害剤

Outline of Final Research Achievements

In recent years, immune checkpoint inhibitors that inhibit PD-1 / PD-L1 interaction have been approved as many cancer types and attracted attention as a new cancer therapy, but due to the characteristics of antibody, soaring drug prices Has begun to be seen as a problem. In this research, we promoted research aimed at searching for cheaper and lower molecular weight compounds with equivalent effect. Firstly, we narrowed down compounds by in silico screening using GPGPU, then established assay systems capable of quantifying the tumor activity of effector cells, and screened.

Free Research Field

分子腫瘍学